BACKGROUND: Primary @entity2 (LELC) is a rare subtype of @entity1149 ( @entity1149 ), and no effective treatments have been defined for advanced disease. @entity4634 ( @entity4634 ) is expressed in a group of @entity5 that may be suitable targets for specific immunotherapy. METHODS: This study investigated the expression and clinical value of @entity4634 in pulmonary LELC. Seventy-nine @entity1 with pulmonary LELC were investigated. @entity982 -embedded @entity5 sections were stained with @entity4634 antibody. Correlations of @entity4634 expression with clinicopathologic parameters and outcomes were analyzed. RESULTS: Fifty @entity1 (63.3%) were @entity4634 positive. The 3-year and 5-year progression-free survival (PFS) rate was 76.0% and 68.0%, respectively, and the 3-year and 5-year @entity1349 ( @entity1349 ) rate was 88.0% and 79.0%, respectively. Kaplan-Meier analysis revealed that @entity1 with positive @entity4634 expression had longer PFS and @entity1349 than those with negative @entity4634 expression (P=0.019 and P=0.042, respectively). In a multivariate Cox regression model including age, @entity5 size, stage, and @entity4634 expression status, the latter three factors were found to be independent predictors of PFS (P=0.023, P=0.000, and P=0.009, respectively), but only stage was found to be an independent factor for @entity1349 (P=0.007), and @entity4634 expression status showed a trend to be independently correlated with @entity1349 (P=0.080). CONCLUSION: Our results showed that a large proportion of @entity1 with pulmonary LELC had positive expression of @entity4634 , supporting the potential use of anti-PD-1/ @entity4634 -targeted therapies in this distinct type of @entity1149 .

Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4634 :: ('29126', 'Gene') :: ['Programmed cell death-ligand 1', 'PD-L1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['pulmonary lymphoepithelioma-like carcinoma'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['Paraffin'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity2 :: (MESH:D008175,Disease) :: ['pulmonary lymphoepithelioma-like carcinoma']
